Published May 2026. Written by the Upwell Health Collective clinical team with care for every woman navigating this transition. Clinically reviewed May 2026. Next review November 2026. For educational purposes only — please consult your GP, women's health specialist or allied health team for individualised care.
This guide was written for one of our own — a sister who asked. To every woman reading: you are not broken, you are not alone, and there is so much more help available to you than the silence of the past generation suggested. With love, Team Upwell.
Related reading from Upwell Health:
• The Disc Injury Directory 2026
• The Shoulder Pain Master Guide 2026
• Pain Is Not Damage: Hurt vs Harm
If you are somewhere between 35 and 65 and life feels different lately — your sleep is broken, your body aches in places that didn't ache before, your mood is unfamiliar to you, your memory has holes in it, and you are wondering what is happening to you — five things to know before anything else:
1/ You are not imagining it. Perimenopause and menopause cause real, measurable physiological changes across every major system in the body — musculoskeletal, cardiovascular, neurological, urogenital, metabolic, and emotional. The symptoms you are feeling are not weakness, they are not in your head, and they are not your fault.
2/ This is not a disease. It is a developmental life stage — like puberty in reverse — that approximately 51% of humans will experience. Around 1.2 billion women globally will be postmenopausal by 2030. You are joining the largest sisterhood there is.
3/ There is more help available than ever before. The International Menopause Society released brand new global consensus guidelines in December 2025. Menopause hormone therapy (MHT) has been comprehensively reframed — it is now considered safe and highly effective for the majority of symptomatic women. Two new non-hormonal medications (fezolinetant 2023, elinzanetant October 2025) directly target hot flashes. The musculoskeletal syndrome of menopause was formally named in October 2024 — finally giving a name to the joint pain, muscle loss, and frozen shoulders that 70% of women experience.
4/ Lifestyle is more powerful than most people realise. Resistance training, aerobic exercise, sleep hygiene, nutrition, stress management, and pelvic floor physiotherapy each have strong 2024–2026 evidence for managing symptoms, protecting long-term health, and adding quality years to life.
5/ You can thrive in this season, not just survive it. Many women describe postmenopause as the most empowered, clear-headed, and capable phase of their lives. The years on the other side of this transition can be your best ones — but they are built by the choices you make now.
This guide brings together the most current evidence from 2023–2026 across hormones, symptoms, physiology, lifestyle medicine, mental health, pelvic health, musculoskeletal care, and emerging therapies. It is approximately 15,000 words. Take your time with it. Read it in chunks. Come back to it. Share it with the women in your life who need it.
The language gets confused easily, so let's get clear from the start.
Perimenopause is the transitional phase leading up to menopause. It begins when the ovaries start producing oestrogen and progesterone more erratically, and ends 12 months after the final menstrual period. Perimenopause typically starts in the early-to-mid 40s, but can begin in the late 30s. The average duration is 4–7 years, though it can stretch to a full decade. This is the phase where most symptoms first appear — and crucially, where most women are still having periods, so the connection to hormones is often missed.
Menopause is technically a single day — the day that marks 12 consecutive months without a menstrual period. The average age of menopause in Australian women is 51, though anywhere between 45 and 55 is considered normal. Menopause before 40 is called premature ovarian insufficiency (POI); menopause between 40–44 is called early menopause. Both have different management considerations and warrant specialist input.
Postmenopause is the phase that begins the day after the menopause anniversary and lasts the rest of your life. The first 10 years of postmenopause are the period of greatest hormonal recalibration and where many of the long-term health risks (bone loss, cardiovascular changes, genitourinary changes) take shape.
The medical framework for staging this transition is the STRAW+10 system (Stages of Reproductive Aging Workshop, updated 2012). It uses menstrual cycle patterns and supportive hormone markers to define eight stages, from reproductive age through to late postmenopause. The most clinically relevant stages are:
• Late reproductive (Stage −3) — subtle changes in cycle length and flow, declining fertility.
• Early menopausal transition (Stage −2) — persistent variability of ≥7 days difference in consecutive cycles. Symptoms may or may not have started.
• Late menopausal transition (Stage −1) — ≥60 days of amenorrhoea (missed period). Vasomotor symptoms typically present. Lasts 1–3 years.
• Early postmenopause (Stage +1a, +1b, +1c) — the first 5 years after the final menstrual period. Symptoms often peak here.
• Late postmenopause (Stage +2) — 5+ years after the final menstrual period.
For most women in Australia over 45, blood tests (FSH, oestradiol) are not needed to diagnose perimenopause — the diagnosis is clinical, based on symptoms and cycle changes. Hormones fluctuate so wildly during perimenopause that a blood test on any single day can be misleading. NICE (UK) and Australasian Menopause Society guidelines are explicit on this. The exception is women under 45, where hormone testing helps rule out other causes.
The story of the menopausal transition is the story of the ovaries gradually winding down. From your late 30s onward, the number of viable egg follicles in your ovaries declines steeply. Each follicle produces oestrogen as it matures — so as the follicles run out, oestrogen production becomes increasingly erratic, then gradually falls. Progesterone, made after ovulation, falls even earlier, because anovulatory cycles (cycles without ovulation) become more common in your 40s.
The pituitary gland, sensing falling oestrogen, ramps up follicle-stimulating hormone (FSH) and luteinising hormone (LH) in an attempt to push the ovaries to produce more. This is why FSH is elevated in late perimenopause and postmenopause — but it fluctuates so wildly in early perimenopause that it's an unreliable diagnostic marker.
Oestrogen is not just a reproductive hormone. It has receptors in almost every tissue in the body. When oestrogen falls, the downstream effects ripple across:
• The brain — oestrogen influences serotonin, dopamine, GABA, sleep architecture, memory consolidation, and thermoregulation in the hypothalamus.
• The bones — oestrogen restrains bone resorption. When it falls, bone is lost rapidly — up to 20% of bone density can be lost in the first 5–10 years of postmenopause.
• The cardiovascular system — oestrogen has favourable effects on cholesterol, vascular elasticity, and inflammation. Loss of oestrogen begins a transition to a higher cardiovascular risk profile.
• The musculoskeletal system — oestrogen has anti-inflammatory effects on joints, supports tendon and ligament integrity, and contributes to muscle stem cell function.
• The genitourinary system — oestrogen maintains the thickness, elasticity, and lubrication of the vaginal and urethral tissues, and the integrity of pelvic floor support.
• The skin and connective tissue — collagen production declines, skin thins, joints feel "creaky".
• Metabolism — insulin sensitivity, body composition, and central fat distribution all shift.
When you understand this, the symptoms make sense. They are not random. They are the predictable downstream consequences of a major endocrine recalibration.
The cultural script for menopause is hot flashes and that's about it. The reality is dramatically broader. The Australian Women's Midlife Years (AMY) Study — a nationally representative cross-sectional study of 5,500+ Australian women aged 40–69 published in 2025 — documented the prevalence and severity of dozens of symptoms across the menopause transition. The findings transformed our understanding of what "normal" looks like.
• Hot flashes (hot flushes) — sudden waves of heat, flushing, and sweating. Affect up to 80% of women.
• Night sweats — hot flashes at night, often drenching, often waking you.
• Cold flashes — less talked about, but real. Sudden chills, often after a hot flash.
• Heart palpitations — sensations of skipped beats or racing heart, particularly at rest or during hot flashes.
• Insomnia — difficulty falling asleep, particularly common in late perimenopause.
• Sleep maintenance issues — waking at 2–4 AM and being unable to get back to sleep.
• Sleep fragmentation — lighter, less restorative sleep even when you do stay asleep.
• Restless legs — more common in perimenopause.
• Sleep apnoea — risk rises substantially after menopause.
• Anxiety — often experienced as a new or returning condition.
• Depression — risk of new-onset depression rises 2–4 fold during perimenopause, particularly in women with prior history of hormone-related mood symptoms (PMS, PMDD, postnatal depression).
• Rage and irritability — often described as "perimenopausal rage", a disproportionate emotional intensity.
• Mood swings — emotional volatility cycle-to-cycle and day-to-day.
• Loss of confidence — often described as feeling "like a different person".
• Panic attacks — new onset.
• Brain fog — difficulty with concentration, sustained attention, and quick recall.
• Word-finding difficulty — the word you're looking for sitting just out of reach.
• Short-term memory lapses — forgetting why you walked into a room.
• Reduced mental clarity — a feeling that your brain is moving slower than it used to.
• Joint pain (arthralgia) — frequently affects fingers, knees, hips, shoulders.
• Muscle aches and stiffness — often worse in the morning.
• Frozen shoulder (adhesive capsulitis) — dramatically more common in perimenopausal women.
• Tendinopathies — plantar fasciitis, lateral hip pain (gluteal tendinopathy), tennis elbow, rotator cuff issues.
• Loss of muscle mass and strength (sarcopenia) — accelerates after menopause.
• Reduced exercise tolerance — "I just can't recover like I used to."
• Vaginal dryness — affecting up to 84% of postmenopausal women.
• Dyspareunia (painful sex) — a major contributor to relationship distress.
• Vulval itching, burning, irritation.
• Urinary urgency and frequency.
• Recurrent urinary tract infections.
• Stress urinary incontinence — leaking with cough, sneeze, or exercise.
• Pelvic organ prolapse symptoms — sensation of heaviness or bulging.
• Skin changes — dryness, thinning, loss of elasticity, increased sensitivity, formication (the sensation of insects crawling on the skin).
• Hair changes — thinning, texture changes, facial hair, scalp hair loss.
• Weight gain — particularly central adiposity (around the waist).
• Digestive changes — bloating, reflux, altered bowel habits.
• Migraines and headaches — can worsen or change pattern.
• Tinnitus and vertigo.
• Dry eyes, mouth.
• Dental changes — gum recession, sensitivity.
• Changes in body odour.
• Loss of libido.
• Reduced energy and fatigue.
• Allergic responses changing — new sensitivities, food intolerances.
If you read this list and recognised yourself, you are far from alone. Most women experience clusters of these symptoms, not all of them — and the severity is highly individual. But the cluster pattern is real, the prevalence is high, and the connection to oestrogen withdrawal is biologically well-established.
This deserves its own deep section, because it is the area where Upwell can make the biggest difference — and because, until very recently, this cluster of symptoms was massively under-recognised.
In October 2024, a landmark paper in Climacteric (the journal of the International Menopause Society) coined the term Musculoskeletal Syndrome of Menopause (MSM). The authors — Vincent, Wright and colleagues — finally gave a name to a constellation of musculoskeletal changes that orthopaedic surgeons, physiotherapists, and women themselves had been observing for decades without an organising framework.
MSM is the umbrella term for a cluster of musculoskeletal changes driven by the decline in oestradiol during the menopause transition. It includes:
• Generalised joint pain (arthralgia) — affecting more than 50% of menopausal women.
• Muscle pain (myalgia) and stiffness.
• Loss of lean muscle mass (sarcopenia) — accelerates significantly after the final menstrual period.
• Loss of bone density leading to osteopenia and osteoporosis — up to 20% bone loss in the first 5–10 years.
• Increased risk of fracture.
• Progression of osteoarthritis.
• Increased tendon and ligament injury — plantar fasciitis, rotator cuff tendinopathy, hip and knee tendinopathies all increase.
• Adhesive capsulitis (frozen shoulder) — dramatically more common in women aged 40–60.
• Cartilage matrix fragility.
The headline numbers from the 2024 paper are striking: more than 70% of women experience musculoskeletal symptoms during the menopause transition, and approximately 25% will be disabled by them. That's roughly 1 in 4 women experiencing significant functional disability — in many cases without anyone connecting the dots back to hormonal change.
Oestradiol — the most active form of oestrogen — is a powerful anti-inflammatory hormone and a key regulator of musculoskeletal tissue. When oestradiol falls:
• Inflammation rises — systemic inflammatory markers (IL-6, TNF-alpha) increase, contributing to joint pain.
• Bone resorption increases — osteoclast activity outpaces osteoblast activity, leading to net bone loss.
• Muscle stem cell function declines — satellite cells become less responsive, slowing muscle repair and growth.
• Tendon and ligament structure changes — collagen turnover shifts, increasing susceptibility to injury.
• Cartilage maintenance declines — chondrocyte function is impaired, accelerating osteoarthritis.
Most women describe MSM as something like: "I wake up stiff. My fingers hurt when I grip things. My shoulder has been niggling for months and now it's properly frozen. I've put on weight even though I'm eating the same. I can't recover from my workouts. Walking up stairs feels harder than it should. My personal trainer has been pushing me on weights but I just feel weaker."
This is not getting old. This is hormonal. And it is highly treatable.
This is the single biggest reason why allied health — physiotherapy, exercise physiology, clinical Pilates, myotherapy — should be a core part of every woman's menopause care plan. MSM is treatable through targeted, well-prescribed, well-progressed exercise and movement work. It responds to strength training. It responds to load management. It responds to manual therapy adjuncts when used appropriately. It responds beautifully to multidisciplinary, individualised care — which is exactly what we do.
If there is one area where the conversation has changed most dramatically in the past 5 years, it is MHT (formerly called HRT — hormone replacement therapy). The story is worth telling properly, because the cultural memory still carries decades of fear that the current evidence does not support.
In 2002, the initial publication of the WHI study — a large US randomised trial of MHT — reported an increased risk of breast cancer and cardiovascular events. The findings made global headlines. Within 18 months, MHT prescribing dropped by 80% in many Western countries. A generation of women were told to stop their MHT and a generation of doctors stopped prescribing it.
What followed was 20 years of careful re-analysis. The original WHI results were nuanced significantly by re-examining the data by age at MHT initiation, type of MHT, route of delivery, and duration of use. The picture that has emerged is dramatically different from the 2002 headlines.
The International Menopause Society released its updated global recommendations in December 2025 (Climacteric, Vol 28, Issue 6, Panay et al). The key findings:
1/ MHT remains the gold standard treatment for vasomotor symptoms (hot flashes, night sweats). Nothing else comes close in terms of effect size and reliability.
2/ The benefits outweigh the risks for the majority of healthy women under 60 (or within 10 years of menopause) with bothersome symptoms. This is now a strong consensus position across all major menopause societies (IMS, NAMS/Menopause Society, AMS, BMS).
3/ Timing matters — the "window of opportunity" hypothesis. MHT initiated within 10 years of menopause appears to have favourable or neutral effects on cardiovascular outcomes. Initiation beyond 10 years carries a less favourable risk profile.
4/ Route of delivery matters. Transdermal oestradiol (patches, gels, sprays) bypasses the liver and does not appear to increase the risk of venous thromboembolism (blood clots) or stroke in observational data. Oral oestrogen carries a small but measurable increase in these risks. For most women now, transdermal is the preferred route.
5/ Type of progesterone matters. Micronised progesterone (Prometrium, Utrogestan) appears to have a more favourable risk profile than older synthetic progestogens. It is now first-line in most international guidelines.
6/ Vaginal oestrogen is exceptionally safe. Low-dose local vaginal oestrogen (cream, pessary, ring) treats genitourinary syndrome of menopause with negligible systemic absorption and is now considered appropriate even for many women who cannot take systemic MHT — including most women with a history of breast cancer (with shared decision-making).
7/ MHT is not indicated for cardiovascular disease prevention. The IMS is explicit on this. MHT is for symptom relief and quality of life — cardiovascular and bone benefits are welcome but not the primary indication.
8/ The dementia question has been largely answered. A major systematic review published in The Lancet Healthy Longevity in December 2025 — analysing data from over one million participants — found no significant association between MHT and dementia risk, in either direction. MHT decisions should be made on the basis of symptom relief, not on dementia prevention or fear of dementia harm.
• Women under 60 (or within 10 years of menopause) with bothersome vasomotor symptoms.
• Women with premature ovarian insufficiency or early menopause — oestrogen replacement is recommended at least until the age of natural menopause to protect bone and cardiovascular health.
• Women with significant genitourinary symptoms (local vaginal oestrogen).
• Women at high risk of osteoporosis, particularly with concurrent symptoms.
• Women with low mood related to menopause, where MHT may improve symptoms even when antidepressants alone are insufficient.
• History of breast cancer — systemic MHT generally contraindicated; vaginal oestrogen often acceptable with shared decision-making.
• History of venous thromboembolism or stroke — transdermal oestrogen preferred if MHT is needed.
• Active liver disease.
• Unexplained vaginal bleeding (needs investigation first).
• Active or recent cardiovascular disease — case-by-case discussion.
In November 2025, the US Department of Health and Human Services announced changes to the black box warnings on MHT products — acknowledging that the older blanket warnings did not reflect current evidence. The IMS welcomed the changes for vaginal oestrogen specifically (where systemic absorption is negligible) while continuing to advocate for evidence-based individualised counselling on systemic MHT.
Many GPs are still catching up with the post-2024 evidence base. If your GP is hesitant, you have options. Australian Menopause Society (AMS) maintains a directory of menopause-experienced GPs. Some specific things to ask about:
• "Can we discuss transdermal oestradiol and micronised progesterone specifically?"
• "What's my individual risk–benefit profile given my age, time since menopause, and family history?"
• "Can I trial MHT and reassess in 3 months?"
• "What's the lowest effective dose for my symptoms?"
• "Could vaginal oestrogen help with my urinary or vaginal symptoms even if I don't want systemic MHT?"
Shared decision-making is the gold standard. There is no single right answer for every woman — but there is a right process, and that process starts with good information and an unhurried conversation.
For women who cannot, should not, or prefer not to take MHT, the past two years have brought a transformation in non-hormonal options.
These are genuinely new medications that target the underlying neural mechanism of hot flashes. Hot flashes are driven by KNDy neurons in the hypothalamus — the neurons that regulate body temperature. When oestrogen falls, these neurons become hyperactive, producing the abrupt thermoregulatory dysregulation we feel as a hot flash. NK3 receptor antagonists dampen this neural over-activity directly.
Fezolinetant (Veozah) — the first NK3 antagonist, FDA approved May 2023. The SKYLIGHT 1, 2, and 4 trials demonstrated meaningful reductions in hot flash frequency and severity at 12 weeks, sustained at 52 weeks. Also approved in Australia. Particularly useful for women with contraindications to MHT (e.g. history of breast cancer).
Elinzanetant (Lynkuet) — the first dual NK1/NK3 receptor antagonist, FDA approved October 2025. Already approved in Australia. The dual mechanism appears to offer additional sleep and mood benefits beyond hot flash reduction. Available in Australia from late 2025.
• SSRIs and SNRIs — paroxetine, venlafaxine, desvenlafaxine, escitalopram all have evidence for reducing hot flashes. Particularly useful when mood symptoms coexist.
• Gabapentin and pregabalin — evidence for reducing hot flashes and night sweats, particularly the sleep-disrupting kind.
• Clonidine — older option with modest effect.
• Oxybutynin — anticholinergic with evidence for hot flash reduction.
• Cognitive behavioural therapy (CBT) for menopause — strong evidence for hot flash distress, sleep, and mood, with effect sizes comparable to medication in some studies. The Hunter and Smith protocol is the most established.
• Mindfulness-based interventions — reduce hot flash bothersomeness and improve mood.
Many supplements and complementary approaches are marketed for menopause. The evidence is variable. Some, like black cohosh and red clover isoflavones, have modest evidence for hot flash reduction in some studies but mixed in others. Some, like bioidentical compounded hormones, lack the quality evidence base of standardised pharmaceutical MHT. Always discuss complementary options with your prescribing clinician — not all supplements are benign, and some can interact with other medications.
Of all the lifestyle interventions for menopause, exercise has the strongest, broadest, most consistent evidence base. It improves vasomotor symptoms (modestly), sleep, mood, cognition, bone density, muscle mass, body composition, cardiovascular risk, joint pain, balance, fall risk, and overall quality of life. Multiple systematic reviews published in 2025 reinforce this evidence.
And yet — exercise is consistently the most under-prescribed and under-supported intervention in mainstream menopause care.
The 2025 Hejazi network meta-analysis (Archives of Osteoporosis, July 2025) of exercise modalities for postmenopausal bone health concluded that combined aerobic and resistance training produces the strongest effects on bone mineral density. The 2025 Optimal Resistance Training Parameters review (Journal of Orthopaedic Surgery and Research, May 2025) confirmed that resistance training drives improvements in lumbar spine, femoral neck, and total hip bone density.
The most exciting development is high-intensity resistance and impact training (HiRIT). The LIFTMOR trial and the MEDEX-OP randomised controlled trial (Belinda Beck and team, Queensland) demonstrated that 8 months of supervised HiRIT improved lumbar spine BMD by ~4% compared to low-intensity exercise, in postmenopausal women with low BMD. Adherence was over 90%. Critically, HiRIT was safe and well tolerated even in women with osteoporosis.
The message: postmenopausal women need to lift heavy, with proper supervision and progression. Not light pink dumbbells. Real, progressive, challenging resistance training.
Resistance training — the cornerstone. 2–3 sessions per week, targeting all major muscle groups, progressively increasing load over months. Compound movements (squat, deadlift, hip hinge, press, pull) form the foundation. Working up to 5–8 rep range at challenging loads (70–85% of 1RM) drives the strongest bone and muscle adaptation. This is uncomfortable. It should be supervised, particularly early on. The discomfort is the point — your body adapts to the loads you give it.
Impact training — for bone health. Jumping, hopping, plyometrics, and high-impact movements stimulate bone formation. The HiRIT protocols combine heavy resistance with low-volume impact work — 5 sets of 5 reps of squat, deadlift, overhead press, plus chin-ups and supported jump landings. Total session time around 30 minutes.
Aerobic exercise — for cardiovascular and metabolic health. 150–300 minutes of moderate-intensity aerobic activity per week (brisk walking, cycling, swimming) or 75–150 minutes of vigorous activity. Helps insulin sensitivity, sleep, mood, body composition.
High-intensity interval training (HIIT). Time-efficient. Strong evidence for cardiovascular and metabolic benefits. Particularly useful for women time-poor in midlife.
Balance and falls prevention. Standing on one leg, tai chi, yoga, dynamic balance work. Critically important in late perimenopause and postmenopause as fracture risk rises.
Flexibility and mobility. Yoga, Pilates, stretching. Important for joint health, posture, and the felt sense of being in your body.
Start where you are. Walking. Body-weight squats. Gentle Pilates. The wins in the first 3 months will be substantial — your nervous system adapts before your muscle does, you'll feel stronger before you look stronger. The principle is gradual progressive overload — you do not need to start with heavy lifting. You just need to start, and then do slightly more next week than this week.
Get a DXA scan. Talk to your GP about pharmacotherapy if indicated. Then — critically — get to an exercise physiologist or physiotherapist who knows the HiRIT evidence. Supervised progressive resistance and impact training is one of the highest-leverage interventions you can make. Bone responds to load. You can build bone in your 50s, 60s, and beyond — the evidence is unambiguous.
The nutrition landscape for menopause is full of noise. The evidence-based principles are surprisingly stable and unsexy. Here is the synthesis:
Anabolic resistance — the reduced muscle protein synthesis response to protein — increases with age and with declining oestrogen. The practical implication: postmenopausal women need more protein per meal than they did at 30, not less. Current evidence supports 1.2–1.6 g/kg body weight per day, distributed across 3–4 meals at 25–40g per meal. For a 65 kg woman, that's 80–105g per day. Most midlife women are eating well below this.
Practical sources: Greek yoghurt, cottage cheese, eggs, fish, chicken, lean red meat, tofu, tempeh, legumes, lentils, protein powder (whey or plant-based).
For bone health, 1,000–1,200 mg calcium per day is the standard recommendation. Best sourced from food (dairy, fortified plant milks, sardines, leafy greens, tofu). Supplementation only if dietary intake is insufficient — large-dose calcium supplementation has its own risks. Vitamin D — critical for calcium absorption. Australian guidelines recommend supplementation in women with low sun exposure or documented deficiency. Get a blood test.
Strong evidence for cardiovascular health, cognitive function, and overall longevity in postmenopausal women. Emphasises vegetables, fruit, whole grains, legumes, olive oil, fish, moderate dairy, modest red meat, limited processed food. Not a diet — a way of eating.
Soy, flaxseed, and legumes contain phytoestrogens — plant compounds with weak oestrogen-like activity. Modest evidence for some symptomatic benefit, particularly when consumed regularly. Soy is safe for the vast majority of women, including those with a history of breast cancer (the older concerns have largely been resolved by contemporary evidence).
• Alcohol — worsens hot flashes, sleep, mood, anxiety, and breast cancer risk. The threshold for problems is lower in midlife. Many women find dramatic improvements by reducing alcohol significantly or eliminating it.
• Refined sugar and ultra-processed food — contribute to weight gain, inflammation, and metabolic dysfunction.
• Caffeine — for some women, dramatically worsens hot flashes and sleep. Worth trialling a reduction or cutting after midday.
• Smoking — brings menopause forward by 1–2 years, worsens hot flashes, increases osteoporosis risk, doubles cardiovascular risk. The highest-leverage change available.
• Fibre — 25–38g per day. Supports gut microbiome, glucose regulation, and bowel health.
• Omega-3 fatty acids — oily fish 2–3 times per week, or supplementation. Cardiovascular, mood, and inflammation benefits.
• Hydration — oestrogen withdrawal affects thirst signalling. Many midlife women are mildly chronically dehydrated.
• Whole foods generally — the most important nutritional intervention is the broad shift toward whole, minimally processed, nutrient-dense eating.
Sleep is where many menopausal symptoms compound. Hot flashes wake you. Disrupted sleep worsens mood, cognition, weight, glucose regulation, and pain sensitivity. Poor sleep makes everything else worse — and improving sleep makes everything else better.
Up to 60% of perimenopausal and postmenopausal women report sleep disturbances. The mechanisms are multifactorial: vasomotor symptoms disrupting sleep architecture, anxiety and depression interfering with sleep onset, restless legs, sleep apnoea (which rises substantially after menopause), and oestrogen's direct effects on sleep regulation in the hypothalamus.
1/ Treat the vasomotor symptoms if they're the main driver. MHT or NK3 antagonists (especially elinzanetant which has sleep-specific benefits) can transform sleep in women whose insomnia is largely night-sweat driven.
2/ Get screened for sleep apnoea. Postmenopausal women have a substantially higher risk than premenopausal women. Snoring, witnessed apnoeas, morning headaches, and daytime sleepiness warrant a sleep study referral.
3/ Implement a serious sleep hygiene routine. Consistent wake time. Bedroom cool (17–19°C is optimal for menopausal women). Dark. Quiet. No screens 30–60 minutes before bed. Wind-down ritual.
4/ CBT for insomnia (CBTi). Strongest evidence base for chronic insomnia. Available online (Sleepio, Sleep Reset) or with a clinical psychologist.
5/ Limit alcohol — particularly evening alcohol. Alcohol fragments sleep and worsens vasomotor symptoms in the second half of the night.
6/ Caffeine. No caffeine after midday for most women.
7/ Exercise — but not too close to bedtime. Aerobic exercise earlier in the day improves sleep quality. Evening high-intensity exercise can interfere with sleep onset.
8/ Mindfulness, magnesium, and other adjuncts. Mindfulness-based stress reduction (MBSR) has solid evidence for improving sleep in midlife women. Magnesium glycinate has modest evidence for sleep onset. Melatonin can help in selected cases.
The mental health story of menopause has been one of the most under-recognised aspects of women's health — and one of the most damaging when missed.
The risk of new-onset depression is 2–4 times higher during perimenopause than during the reproductive years. Women with a prior history of hormone-related mood symptoms — premenstrual syndrome, premenstrual dysphoric disorder (PMDD), postnatal depression — are at particularly elevated risk. Anxiety, irritability, and rage are commonly reported. Many women describe "not feeling like themselves".
Oestrogen modulates serotonin, dopamine, and GABA systems. Fluctuating oestrogen in perimenopause produces neurotransmitter instability — which manifests as mood instability. Sleep disruption from night sweats compounds the picture. Cognitive symptoms erode self-confidence. Body changes affect identity. Life stage stressors (teenage children, ageing parents, career inflection points, relationship changes) often layer on top.
1/ Naming what's happening. Many women describe enormous relief from finally understanding that perimenopause is the driver of mood changes they've been blaming on themselves.
2/ MHT can substantially help mood — particularly when mood symptoms are clearly cycle-related or peri-menopausal. Multiple trials confirm this. In some women, MHT alone resolves mood symptoms that did not respond to antidepressants.
3/ Antidepressants — specifically the SSRIs and SNRIs — are first-line for clinical depression and often combined with MHT.
4/ Cognitive behavioural therapy — strong evidence for menopause-specific CBT protocols (Myra Hunter's work) for both mood and vasomotor symptom distress.
5/ Exercise — antidepressant-equivalent effect sizes in meta-analyses of moderate-to-severe depression. Powerful at any age but particularly in midlife.
6/ Psychology, social support, and self-compassion. The midlife experience is often deeply social and contextual. A skilled psychologist can be transformative.
7/ If you are experiencing thoughts of self-harm or suicide, seek help now. Lifeline 13 11 14. Beyond Blue 1300 22 4636. Your GP. The emergency department. You are not alone, and there is good help available.
Brain fog is among the most commonly reported and most distressing symptoms of perimenopause. The good news is that the contemporary research paints a hopeful picture.
The 2025 systematic review presented at the Menopause Society annual meeting confirmed that menopause is associated with measurable structural and functional brain changes. But — critically — these changes appear to be largely transient and adaptive. The brain reshapes during the menopausal transition, and after a period of adjustment, performance typically returns to baseline or near-baseline. The 2026 Nature npj Women's Health cohort study of over 1,000 women confirmed that objective cognitive performance differed only minimally across menopause stages.
The 2025 UCL/WHO systematic review in The Lancet Healthy Longevity — the largest of its kind — found no significant association between MHT and dementia risk in either direction. The decision about MHT should be based on symptom relief, not on hopes or fears around dementia.
• Sleep — protect it ferociously. Most cognitive symptoms improve substantially when sleep improves.
• Exercise — particularly aerobic exercise. Robust evidence for cognitive benefits.
• Stress reduction. Chronic stress impairs working memory and prefrontal function.
• Cognitive engagement. Use the brain. Learn new things. Read complex material. Play strategic games. Have demanding conversations.
• Social connection. One of the strongest predictors of cognitive health in longitudinal studies.
• Mediterranean diet. Cognitive benefits in multiple cohorts.
• MHT if appropriate. Some women experience meaningful cognitive improvement on MHT, particularly when hot flashes and sleep are the underlying drivers.
• Reassurance. The catastrophising about dementia in midlife women is common and often unfounded. The cognitive symptoms of perimenopause are almost always reversible.
Heart disease is the leading cause of death in Australian women — not breast cancer. Menopause marks a meaningful transition in cardiovascular risk profile that often goes underrecognised.
• LDL cholesterol rises. HDL cholesterol falls.
• Insulin sensitivity declines. Type 2 diabetes risk rises.
• Blood pressure tends to rise.
• Vascular elasticity declines.
• Central adiposity (waist fat) increases — a stronger cardiovascular risk marker than overall weight.
• Inflammatory markers rise.
The 10–15 years post-menopause are the period of greatest cardiovascular recalibration. The choices made in this window have outsized effects on long-term outcomes.
• Know your numbers. Blood pressure, cholesterol panel, fasting glucose, HbA1c, waist circumference. Get them checked at perimenopause baseline and review annually.
• Exercise — aerobic and resistance. The single most powerful intervention.
• Mediterranean dietary pattern. Decades of evidence for cardiovascular protection.
• Sleep apnoea screening. Often missed in postmenopausal women.
• Stress and social connection. Both meaningful cardiovascular risk factors.
• Tobacco — cease. The single highest-leverage cardiovascular change.
• Alcohol — limit. Cardiovascular benefits of moderate intake have been substantially downgraded in recent evidence.
• Treat hypertension, dyslipidaemia, and diabetes aggressively. The midlife window is the highest-leverage intervention period.
Osteoporosis affects 1 in 4 Australian women over 50. The first 5–10 years of postmenopause are when most bone loss occurs — up to 20% of total bone mass. Hip fractures in postmenopausal women carry a 12-month mortality of 20–30%. Bone health is not a glamorous topic but it is one of the most important.
• Get a DXA scan. Baseline scan in early postmenopause; repeat every 2–5 years depending on baseline and risk factors. Subsidised by Medicare for women aged 70+ and earlier with risk factors.
• Calcium 1,000–1,200 mg/day, vitamin D as indicated.
• Resistance training. Heavy. Progressive. Supervised.
• Impact training where appropriate. Jumping, hopping, plyometrics. The HiRIT evidence.
• Protein 1.2–1.6 g/kg/day.
• Avoid smoking. Limit alcohol.
• MHT reduces fracture risk by 30–40% in postmenopausal women and is appropriate as bone-protection in symptomatic women under 60.
• Bisphosphonates, denosumab, and other osteoporosis medications as indicated by DXA results and fracture risk.
• Falls prevention. Balance training, vision and footwear review, home safety audit.
Genitourinary syndrome of menopause (GSM) is one of the most under-treated aspects of menopause care — not because it doesn't matter, but because the cultural taboos around vaginal and urinary symptoms keep women silent. The 2025 AUA/SUFU/AUGS Guideline for GSM is explicit: pelvic floor physical therapy is a first-line treatment alongside low-dose vaginal oestrogen.
• Vaginal dryness, itching, burning, irritation.
• Painful sex (dyspareunia).
• Loss of sensation, reduced arousal, orgasmic difficulty.
• Urinary urgency, frequency, nocturia.
• Recurrent urinary tract infections.
• Stress urinary incontinence (leaking with cough, sneeze, exercise, laughter).
• Pelvic organ prolapse symptoms.
• Decreased libido.
The prevalence is staggering — up to 84% of postmenopausal women have some degree of GSM. Yet many never report it to a clinician.
1/ Low-dose vaginal oestrogen. Cream, pessary, or ring. Tiny doses. Negligible systemic absorption. Transformative for vaginal symptoms and many urinary symptoms. Safe even for the vast majority of women with a history of breast cancer (with shared decision-making). One of the most under-prescribed treatments in women's health.
2/ Pelvic floor physiotherapy. The 2025 Spanish systematic review confirmed pelvic floor muscle training improves urinary symptoms, sexual function, quality of life, and pelvic floor strength with no adverse effects. The 2025 European Journal review found a 92% probability of significant improvement in urinary incontinence with PFMT compared to controls.
3/ Vaginal moisturisers and lubricants. Hyaluronic acid-based moisturisers used regularly (not just before sex) maintain vaginal tissue health. Silicone-based or water-based lubricants for intimacy.
4/ DHEA vaginal preparations (prasterone). An alternative or adjunct to vaginal oestrogen.
5/ Vaginal laser and radiofrequency. Emerging evidence; not yet first-line.
6/ Address sexual function holistically. Communication with your partner. Treating co-existing mood and body image concerns. Considering testosterone supplementation in selected cases (off-label in Australia for women but increasingly accepted with specialist input).
This is where Upwell Health Collective comes in. Menopause is not a single-discipline condition — it is a multi-system transition that benefits from a multi-disciplinary team. Our Camberwell clinic brings together physiotherapy, exercise physiology, clinical Pilates, podiatry, and myotherapy under one roof, with a particular focus on women's health.
Here is what working with our team during the menopause transition can look like:
Our physiotherapists are well-trained in the new MSM framework. We assess and treat:
• New-onset joint pain in fingers, hips, knees, shoulders.
• Frozen shoulder — dramatically more common in perimenopausal women. We use the latest evidence-based protocols (see our Shoulder Pain Master Guide).
• Tendinopathies — gluteal tendinopathy, plantar fasciitis, tennis elbow, rotator cuff issues.
• Pelvic floor dysfunction — urinary incontinence, prolapse symptoms, painful sex (with referral to a women's health physiotherapist for internal pelvic floor assessment where indicated).
• Persistent back pain and headaches that have worsened with menopause.
• Education, reassurance, and the Whole Person Pain™ framework for understanding pain that has emerged or worsened during the transition.
Our exercise physiologists (AEPs) deliver the evidence-based exercise prescription that transforms outcomes in menopause:
• Resistance training programs — progressively loaded compound movements, supervised, safe, individualised.
• HiRIT-aligned protocols for women with low bone density or osteoporosis.
• Cardiovascular conditioning — graded aerobic and HIIT programs.
• Balance and falls prevention.
• Return-to-exercise support for women who have stopped exercising and want to restart safely.
• Diabetes, cardiovascular, and metabolic disease management with chronic disease care plan (CDM) referrals.
Reformer and mat-based clinical Pilates is one of the most accessible entry points for women new to exercise or recovering from injury. Particularly valuable for:
• Pelvic floor support and integration.
• Core strength and trunk control.
• Hip and shoulder mobility.
• Body awareness and movement confidence.
• A welcoming pathway back into movement for women who feel disconnected from their bodies.
Foot pain rises with menopause — plantar fasciitis, midfoot arthritis, bunions, fat pad atrophy. Our podiatrists assess, treat, and manage these conditions, supporting your ability to keep moving.
Myotherapy provides hands-on soft tissue treatment that complements active rehabilitation — particularly valuable for the muscular tension, headaches, and flare-ups that often accompany the transition.
Most importantly, our team works together. Your physio, EP, Pilates instructor, and myotherapist communicate. We share the same clinical philosophy and the same evidence base. We refer to and from your GP, specialists, women's health physiotherapists, psychologists, and other professionals as needed. You don't have to coordinate your own care — we do that for you.
A menopause-aware GP. Essential. The Australasian Menopause Society maintains a directory at menopause.org.au. If your current GP is not comfortable with current MHT prescribing, you have the right to seek a second opinion.
A women's health physiotherapist for internal pelvic floor assessment if you have prolapse symptoms, sexual pain, or complex incontinence.
A clinical psychologist with experience in midlife women's mental health, particularly if you have a history of hormone-related mood symptoms or current mood/anxiety issues.
A specialist (endocrinologist or gynaecologist with menopause expertise) for complex MHT decisions, premature ovarian insufficiency, or post-cancer menopause care.
A dietitian or nutritionist for individualised nutritional support — particularly valuable for women with weight, glucose, or gut symptom changes.
A pelvic floor coach or peer support group. The community matters.
• Talk to your employer. Australian workplaces are increasingly menopause-aware. Flexible work arrangements, cooling provisions, time off for medical appointments, and mental health leave can all be discussed.
• Communicate with your partner. The relationship transition is real. Many couples benefit from couples therapy in this period.
• Tell your friends. The shame of perimenopause dissolves when you discover that most of your friends are going through something similar.
• Be patient with your children, especially teenagers. The simultaneity of perimenopausal hormones with teenage hormones in the same household is a real thing.
• Australasian Menopause Society (menopause.org.au) — the gold-standard Australian resource. GP directory, fact sheets, evidence summaries.
• Jean Hailes for Women's Health (jeanhailes.org.au) — outstanding patient-facing resources, free fact sheets, women's health helpline.
• Healthtalk Australia — lived experience stories from Australian women.
• Beyond Blue (1300 22 4636) — for mental health support.
• Lifeline (13 11 14) — 24/7 crisis support.
If you're over 40 and your cycles are changing (longer, shorter, heavier, lighter, skipping) and you're experiencing some of the symptoms in this guide — you're almost certainly in perimenopause. Blood tests are usually not needed if you're over 45. Trust your body and your story.
That's a shared decision between you and your GP, ideally a menopause-aware one. For most healthy women under 60 with bothersome symptoms, the benefits of modern transdermal MHT outweigh the risks. But the right answer is individual.
You have the right to a second opinion. The Australasian Menopause Society maintains a directory of menopause-experienced clinicians. The 2024–2026 evidence base is dramatically more supportive of MHT than the post-2002 cultural memory suggests.
Many women gain weight in perimenopause, particularly around the waist. The drivers are multifactorial: insulin sensitivity changes, sleep disruption, muscle mass loss, lifestyle factors, and direct hormonal effects on body composition. It is responsive to exercise (particularly resistance training) and nutrition (particularly adequate protein and reduced alcohol). But be kind to your body — some softening is normal and not a moral failing.
Skin thinning and hair changes are partly hormone-driven. MHT can help. Topical retinoids, vitamin C, and SPF support skin. Minoxidil can help with hair loss. A dermatologist consultation can clarify what's hormone-driven and what's not.
For most women, yes — with the right combination of vaginal oestrogen, pelvic floor support, lubrication, communication, and time. Painful sex is treatable. Loss of libido is treatable. Many women report that postmenopausal sex — once GSM is addressed — is more satisfying than it was for years prior.
Perimenopausal symptoms typically last 4–7 years on average, though up to 10 years is not unusual. Hot flashes can persist for many years into postmenopause for some women. Most other symptoms ease substantially within 5–7 years of the final menstrual period. With good management, the experience can be transformed even when the timeline is long.
The breast cancer risk from contemporary MHT is small — smaller than the risk associated with drinking 2 standard drinks per day, being overweight, or being physically inactive. The absolute risk increase is in the range of 1 additional case per 1,000 women per year of use, primarily with combined oestrogen-progestogen therapy beyond 5 years. Discuss your individual family history and risk factors with your GP. Vaginal oestrogen is essentially risk-free for breast cancer.
Both situations change MHT options. Women without a uterus generally only need oestrogen (no progesterone). Women with a Mirena IUD have endometrial protection from the IUD and may take oestrogen alone alongside it. Discuss with your prescriber.
Possibly. Early perimenopause can begin in the late 30s. Premature ovarian insufficiency (menopause before 40) affects 1–2% of women. If you're under 45 with menopausal symptoms, see your GP for assessment including blood tests.
It depends on how long since your final menstrual period. The 10-year window of opportunity is the most favourable for initiation. Beyond 10 years, the risk–benefit calculation shifts and case-by-case specialist input is generally recommended. Local vaginal oestrogen for GSM remains appropriate at any age.
There is something cultural we need to name. Generations of women have been taught to endure menopause silently. To not complain. To not seek help. To accept symptoms as the price of being a woman. To be embarrassed about night sweats and incontinence and brain fog and the loss of sexual function.
That era is ending.
The 2024–2026 evidence base is the strongest it has ever been. The medical, allied health, and cultural understanding of perimenopause and menopause has expanded dramatically. The treatments available — hormonal, non-hormonal, lifestyle, exercise-based, hands-on — are more sophisticated and more individualised than at any point in history.
You do not have to suffer.
You do not have to navigate this alone.
You can become stronger, more focused, more clear-headed, and more confident in postmenopause than you have been in years. The women who thrive in this transition are not the lucky ones — they are the ones who get the right information, build the right team, make the right lifestyle choices, and refuse to settle for being dismissed.
This is your time. Reach out for help. Ask the questions. Find the practitioners who will listen. Lift the weights. Eat the protein. Sleep the hours. Take the MHT if it's right for you. Address the pelvic floor. Treat the joint pain. Speak to a psychologist. Build your community. And be patient with yourself, because the brain you have on the other side of this transition will likely be one of the best you have ever had.
And whenever you need allied health support, Upwell Health Collective is here. Our Camberwell team works with women through every stage of this transition. To book an appointment, visit upwellhealth.com.au or call our clinic on 03 9882 6485. We bulk-bill where eligible and work with NDIS, DVA, TAC, and WorkSafe.
1. Panay N, Fenton A, Hamoda H, et al. International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause. Climacteric. 2025;28(6):634-656.
2. Menopausal Hormone Therapy—Risks, Benefits and Emerging Options: A Narrative Review. International Journal of Molecular Sciences. 2025;26(22):11098.
3. International Menopause Society. Menopause and MHT in 2024: addressing the key controversies — IMS White Paper. 2024.
4. Vincent AJ, Wright A, et al. The musculoskeletal syndrome of menopause. Climacteric. 2024.
5. Hejazi K, Mohammad Rahimi GR, Hofmeister M. Impact of exercise modalities on bone health: a meta-analysis of aerobic, resistance, and combined training on bone mineral density in postmenopausal women. Archives of Osteoporosis. 2025;20(1):105.
6. Beck BR, et al. The MEDEX-OP randomized controlled trial: bone-targeted exercise with and without antiresorptive bone medication. Journal of Bone and Mineral Research. 2021;36(9):1680-1693.
7. Optimal resistance training parameters for improving bone mineral density in postmenopausal women: systematic review and meta-analysis. Journal of Orthopaedic Surgery and Research. 2025;20:523.
8. Australian Women's Midlife Years (AMY) Study. Prevalence and severity of symptoms across the menopause transition. The Lancet Regional Health Western Pacific. 2025.
9. Australasian Menopause Society. Perimenopause or Menopausal Transition (AMS Information Sheet). 2025.
10. Santoro N, Neal-Perry G, Stute P, et al. Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy. Current Medical Research and Opinion. 2025;41(2):375-384.
11. FDA approval of Elinzanetant (Lynkuet) for moderate to severe vasomotor symptoms due to menopause. October 2025.
12. American Urological Association, SUFU, AUGS. Genitourinary Syndrome of Menopause Guideline. 2025.
13. Pelvic floor muscle training as a treatment for genitourinary syndrome of menopause: systematic review. Fisioterapia. 2025;47(3).
14. Effect of pelvic floor muscle training on urinary incontinence symptoms in postmenopausal women: systematic review and meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2025;304:134-140.
15. UCL/WHO systematic review on menopausal hormone therapy and dementia risk. The Lancet Healthy Longevity. December 2025.
16. Cognition and the menopause transition: cross-sectional evidence from a large community cohort. npj Women's Health. 2026.
17. The Menopause Society. Earlier menopause and reduced cardiac function and brain health. Press release, October 2025.
18. Hunter MS. Cognitive Behaviour Therapy for menopausal symptoms. Climacteric. 2021.
19. Harlow SD et al. Executive summary of the Stages of Reproductive Aging Workshop + 10 (STRAW+10). Menopause. 2012;19(4):387-395.
20. Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions. Clinical Endocrinology. 2025.
21. Effects of different exercise interventions on bone mineral density in elderly postmenopausal women: a network meta-analysis. Frontiers in Physiology. 2025;16:1633913.
22. Exercise for Postmenopausal Bone Health — Can We Raise the Bar? Current Osteoporosis Reports. 2025.
23. Beck BR, Daly RM, Singh MA, Taaffe DR. Exercise and Sports Science Australia (ESSA) position statement on exercise prescription for the prevention and management of osteoporosis. Journal of Science and Medicine in Sport. 2017.
24. Cobin RH, Goodman NF. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause. Endocrine Practice. 2017 (foundational).
25. The North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794 (foundational).
26. Jean Hailes for Women's Health. Menopause Information Resources. jeanhailes.org.au. 2025.
27. FDA Veozah (Fezolinetant) Approval for menopausal symptoms: a new nonhormonal option. Annals of Medicine and Surgery. 2025;87(9):5373-5377.
28. SKYLIGHT 1 and SKYLIGHT 2 trials. The Lancet. 2023.
29. The 2025 IMS World Menopause Day White Paper on lifestyle medicine. International Menopause Society. 2025.
30. Acknowledging the Musculoskeletal Syndrome of Menopause. Pelvic Pain Rehabilitation Clinical Update. 2025.
31. Effects of exercise on bone metabolism in postmenopausal women. Frontiers in Endocrinology. 2025;16:1597046.
32. Comprehensive evidence review on menopausal hormone therapy for breast cancer survivors. Cancer Medicine. 2025.
33. Cognitive functioning in perimenopause: an updated systematic review and meta-analysis. Psychology and Aging. 2025.
34. Pelvic floor muscle rehabilitation for genitourinary syndrome of menopause: why, how and when? Climacteric. 2023.
35. Australian Institute of Health and Welfare. Women's Health Snapshot. 2024.
36. Jean Hailes Women's Health Survey. 2024.
37. RACGP. Aged Care Clinical Guide — Menopause. Royal Australian College of General Practitioners. 2024.
38. World Health Organization. Menopause Position Statement. 2024.
39. Harvard Health Publishing. Musculoskeletal syndrome of menopause. 2025.
40. American Academy of Orthopaedic Surgeons (AAOS). Musculoskeletal Syndrome of Menopause (OrthoInfo). 2026.
A note from Team Upwell
This guide was written with deep care — for one of our own, and for every woman navigating this transition. We have tried to be honest about the challenges, hopeful about the help available, and rigorous about the evidence. We update this guide every six months as the evidence evolves. Our next scheduled review is November 2026.
If something in this guide doesn't sit right, if you spot an error, or if your story should be in here — please reach out. We are here to listen.
You are not broken. You are becoming.
With love and care,
— Team Upwell, Camberwell